Has been used with Anti-Fibroblast growth factor receptor 1 (FGFR1) drug in breast cancer. Evidence that FGFR1 can be used as a independent prognosis marker in ESCC and anti-FGFR1 decreases proliferation via MEK-ERK downstream pathways. The gene discussed is MAP2K7; the disease is esophageal squamous cell carcinoma.